Paul Grasby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paul Grasby has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Phillip J. Cowen
University Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
3 shared publications - Zubin Bhagwagar
Yale University
2 shared publications Andrew D. Lawrence
1 shared publicationAndrew J. Montgomery
Imperial College, School of Medicine, University Department of Psychiatry, Warneford Hospital, Oxford, UK
1 shared publicationDanielle Turner
Dept. of Psychiatry, Cambridge University, UK
1 shared publicationDigby Quested
1 shared publication
Latest Publications
- 31 August 2010
- Published by Elsevier in NeuroImage
- Vol. 52, S93-S94
Association between serotonin transporter binding, physiological and environmental factors in healthy male subjects
- 31 August 2010
- Published by Elsevier in NeuroImage
- Vol. 52, S93-S94
Association between serotonin transporter binding, physiological and environmental factors in healthy male subjects
- 1 December 2007
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 164 (12) , 1858-1865
5-HTT Binding in Recovered Depressed Patients and Healthy Volunteers: A Positron Emission Tomography Study With [ 11 C]DASB
The serotonin transporter (5-HTT) is a key target for selective serotonin reuptake inhibitors and may be involved in the pathophysiology of major depression. It is now possible to image 5-HTT directly in the human brain, but results from studies of acutely depressed patients have been inconsistent. The purpose of this study was to determine whether abnormalities in 5-HTT might be present in recovered depressed patients. The authors measured the binding potential of 5-HTT using [11C]DASB in conjunction with positron emission tomography (PET) in 24 medication-free, recovered depressed male patients and 20 healthy male comparison subjects. The regional estimates of binding potential were obtained using a metabolite-corrected plasma input function method followed by Logan analysis, with the cerebellum as a reference region. The authors found no significant difference in the binding potential of [11C]DASB between the recovered depressed patients and healthy comparison subjects in any of the brain regions (amygdala, anterior cingulate cortex, caudate nucleus, frontal cortex, hippocampus, insula, thalamus, and dorsal raphe) studied. Men who recover from depression have normal availability of 5-HTT in brain regions thought to be involved in the pathophysiology of depression. The findings therefore do not support the proposal that recurrent depression is associated with long-standing deficits in 5-HTT.
- 1 December 2007
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 164 (12) , 1858-1865
5-HTT Binding in Recovered Depressed Patients and Healthy Volunteers: A Positron Emission Tomography Study With [ 11 C]DASB
The serotonin transporter (5-HTT) is a key target for selective serotonin reuptake inhibitors and may be involved in the pathophysiology of major depression. It is now possible to image 5-HTT directly in the human brain, but results from studies of acutely depressed patients have been inconsistent. The purpose of this study was to determine whether abnormalities in 5-HTT might be present in recovered depressed patients. The authors measured the binding potential of 5-HTT using [11C]DASB in conjunction with positron emission tomography (PET) in 24 medication-free, recovered depressed male patients and 20 healthy male comparison subjects. The regional estimates of binding potential were obtained using a metabolite-corrected plasma input function method followed by Logan analysis, with the cerebellum as a reference region. The authors found no significant difference in the binding potential of [11C]DASB between the recovered depressed patients and healthy comparison subjects in any of the brain regions (amygdala, anterior cingulate cortex, caudate nucleus, frontal cortex, hippocampus, insula, thalamus, and dorsal raphe) studied. Men who recover from depression have normal availability of 5-HTT in brain regions thought to be involved in the pathophysiology of depression. The findings therefore do not support the proposal that recurrent depression is associated with long-standing deficits in 5-HTT.
- Open Access
- 1 February 2004
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 61 (2) , 134-142
Presynaptic Dopaminergic Dysfunction in Schizophrenia
The original dopamine (DA) hyperactivity hypothesis of schizophrenia,1 although undergoing revisions and reformulations,2,3 remains a pivotal neurochemical hypothesisof the illness that is yet to be fully confirmed or refuted. Multiple componentsof dopaminergic neurotransmission may cause dopaminergic overactivity, includingincreased DA synthesis, release, receptor number and/or affinity, and DA-mediatedpostsynaptic effector mechanisms. Certain of these processes can be quantifiedin vivo in patients, allowing a more comprehensive test of the DA overactivityhypothesis than was previously available.
- 1 February 2004
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 61 (2) , 134-142
Open AccessPresynaptic Dopaminergic Dysfunction in Schizophrenia
The original dopamine (DA) hyperactivity hypothesis of schizophrenia,1 although undergoing revisions and reformulations,2,3 remains a pivotal neurochemical hypothesisof the illness that is yet to be fully confirmed or refuted. Multiple componentsof dopaminergic neurotransmission may cause dopaminergic overactivity, includingincreased DA synthesis, release, receptor number and/or affinity, and DA-mediatedpostsynaptic effector mechanisms. Certain of these processes can be quantifiedin vivo in patients, allowing a more comprehensive test of the DA overactivityhypothesis than was previously available.
Temporal characterisation of amphetamine‐induced dopamine release assessed with [11C]raclopride in anaesthetised rodents
Competition between endogenous neurotransmitters and radiolabelled tracers, as measured by positron emission tomography (PET), may provide a measure of endogenous neurotransmitter flux in vivo. For example, carbon‐11 labelled raclopride has been effectively used to monitor dopamine release following pharmacological and behavioural manipulations. The current study describes a rodent model of amphetamine‐induced [11C]raclopride reduction, which allowed the characterisation of the dose–response and temporal dynamics of this reduction over a 24‐h time course. Over the range studied, a monotonic dose–response relationship between amphetamine dose and [11C]raclopride reduction was observed. When compared with previously published microdialysis data, an approximate 16% reduction in [11C]raclopride binding potential was associated with a ∼25‐fold increase in extracellular dopamine. A reduction of 20–30% in raclopride binding was observed 30 min after amphetamine injection (4 mg/kg IP). This reduction in [11C]raclopride binding persisted for 4 h but returned to baseline by 8 h. The data suggest a persistent amphetamine‐induced raclopride displacement in rodents and reinforce findings from nonhuman primates that a simple competitive occupancy model may not adequately explain the temporal characteristics of the amphetamine‐induced decrease in radiotracer binding. Synapse 51:206–212, 2004.
Temporal characterisation of amphetamine‐induced dopamine release assessed with [11C]raclopride in anaesthetised rodents
Competition between endogenous neurotransmitters and radiolabelled tracers, as measured by positron emission tomography (PET), may provide a measure of endogenous neurotransmitter flux in vivo. For example, carbon‐11 labelled raclopride has been effectively used to monitor dopamine release following pharmacological and behavioural manipulations. The current study describes a rodent model of amphetamine‐induced [11C]raclopride reduction, which allowed the characterisation of the dose–response and temporal dynamics of this reduction over a 24‐h time course. Over the range studied, a monotonic dose–response relationship between amphetamine dose and [11C]raclopride reduction was observed. When compared with previously published microdialysis data, an approximate 16% reduction in [11C]raclopride binding potential was associated with a ∼25‐fold increase in extracellular dopamine. A reduction of 20–30% in raclopride binding was observed 30 min after amphetamine injection (4 mg/kg IP). This reduction in [11C]raclopride binding persisted for 4 h but returned to baseline by 8 h. The data suggest a persistent amphetamine‐induced raclopride displacement in rodents and reinforce findings from nonhuman primates that a simple competitive occupancy model may not adequately explain the temporal characteristics of the amphetamine‐induced decrease in radiotracer binding. Synapse 51:206–212, 2004.
Tyrosine‐free amino acid mixture attenuates amphetamine‐induced displacement of [11C]raclopride in striatum in vivo: A rat PET study
Previous neurochemical and behavioural studies show that tyrosine depletion using a nutritionally balanced tyrosine‐free amino acid mixture attenuates the dopamine‐releasing and psychostimulant properties of amphetamine. Here we investigate the effect of a tyrosine‐free amino acid mixture on striatal binding of [11C]raclopride, and amphetamine‐induced [11C]raclopride displacement, using positron emission tomography in the rat. Rats were scanned for 60 min after an i.v. injection of ∼11 MBq [11C]raclopride using a quad‐HIDAC system. Amphetamine (2 mg/kg i.p., 30 min prior to scan) caused a 12% reduction in [11C]raclopride distribution volume ratio (DVR) compared to saline‐injected controls. The tyrosine‐free amino acid mixture (1 g/kg i.p.) caused a small (+7%) but statistically insignificant increase in [11C]raclopride DVR and attenuated, although it did not fully block, the amphetamine‐induced reduction. These data are in keeping with previous neurochemical, immunocytochemical, and behavioural studies showing that tyrosine‐free amino acid mixtures reduce dopamine function and offer promise for future PET studies testing the effect of tyrosine‐depleting paradigms on dopamine release in humans. Synapse 51:151–157, 2004.
Tyrosine‐free amino acid mixture attenuates amphetamine‐induced displacement of [11C]raclopride in striatum in vivo: A rat PET study
Previous neurochemical and behavioural studies show that tyrosine depletion using a nutritionally balanced tyrosine‐free amino acid mixture attenuates the dopamine‐releasing and psychostimulant properties of amphetamine. Here we investigate the effect of a tyrosine‐free amino acid mixture on striatal binding of [11C]raclopride, and amphetamine‐induced [11C]raclopride displacement, using positron emission tomography in the rat. Rats were scanned for 60 min after an i.v. injection of ∼11 MBq [11C]raclopride using a quad‐HIDAC system. Amphetamine (2 mg/kg i.p., 30 min prior to scan) caused a 12% reduction in [11C]raclopride distribution volume ratio (DVR) compared to saline‐injected controls. The tyrosine‐free amino acid mixture (1 g/kg i.p.) caused a small (+7%) but statistically insignificant increase in [11C]raclopride DVR and attenuated, although it did not fully block, the amphetamine‐induced reduction. These data are in keeping with previous neurochemical, immunocytochemical, and behavioural studies showing that tyrosine‐free amino acid mixtures reduce dopamine function and offer promise for future PET studies testing the effect of tyrosine‐depleting paradigms on dopamine release in humans. Synapse 51:151–157, 2004.
- 1 October 2003
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 160 (10) , 1887-1889
Reduction of Brain Dopamine Concentration With Dietary Tyrosine Plus Phenylalanine Depletion: An [11C]Raclopride PET Study
Extracellular dopamine concentrations were estimated through measurement of [(11)C]raclopride binding with positron emission tomography after dietary manipulation of the dopamine precursors tyrosine and phenylalanine. Healthy male subjects were scanned on two occasions: once after receiving a balanced amino acid drink and once after receiving a drink mixture from which tyrosine and phenylalanine were omitted. Dietary tyrosine and phenylalanine depletion increased [(11)C]raclopride binding in the striatum by a mean of 6%. The change in [(11)C]raclopride binding correlated significantly with the fall in the ratio of tyrosine and phenylalanine to large neutral amino acids. This is the first demonstration of an effect of a dietary manipulation on brain dopamine release in humans. This result provides support for the further investigation of the role of dietary manipulations in the treatment of neuropsychiatric disorders.
- 1 October 2003
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 160 (10) , 1887-1889
Reduction of Brain Dopamine Concentration With Dietary Tyrosine Plus Phenylalanine Depletion: An [11C]Raclopride PET Study
Extracellular dopamine concentrations were estimated through measurement of [(11)C]raclopride binding with positron emission tomography after dietary manipulation of the dopamine precursors tyrosine and phenylalanine. Healthy male subjects were scanned on two occasions: once after receiving a balanced amino acid drink and once after receiving a drink mixture from which tyrosine and phenylalanine were omitted. Dietary tyrosine and phenylalanine depletion increased [(11)C]raclopride binding in the striatum by a mean of 6%. The change in [(11)C]raclopride binding correlated significantly with the fall in the ratio of tyrosine and phenylalanine to large neutral amino acids. This is the first demonstration of an effect of a dietary manipulation on brain dopamine release in humans. This result provides support for the further investigation of the role of dietary manipulations in the treatment of neuropsychiatric disorders.